Thursday, May 16, 2019
Pneuma Respiratory, Inc., developer of a proprietary breathing-enabled digital inhaler (BDI), and Leads Biolabs Inc. announce an agreement that gives Pneuma a license exclusive to develop a panel of monoclonal antibodies for immunoncology and fusion protein molecules of Leads Biolabs for pulmonary administration of antibodies and Leads molecules. Using the Pneuma digital inhaler platform, the agreement provides access to an unexplored potential for pulmonary administration of Leads immunoncology therapies in the treatment of oncological or immune lung diseases.
In a recent publication, Pneuma announced the completion of a study that demonstrates the feasibility of administering antibodies to the lungs through its digital inhaler platform. This study, carried out in an animal model, indicates that the Pneuma digital inhaler platform can provide a method for the pulmonary administration of monoclonal antibody therapies, which enables the selective treatment of oncological or immune pulmonary diseases.
"This collaboration is an exciting development for the field of immunology," said Dr. Ronald Bukowski , physician emeritus at the Cleveland Clinic Foundation. "Approaches that use local administration of new checkpoint inhibitors may provide new treatment opportunities for patients suffering from a variety of malignancies."
"We are pleased to conclude a license agreement for the Leads Biolabs monoclonal antibody portfolio," said Eric Hunter , CEO and co-founder of Pneuma. "We look forward to working with your team to conduct studies that can generate positive changes in the future treatment of non-small cell lung cancer."
Dr. Xiaoqiang Kang , President and CEO of Leads Biolabs, said: "We are very excited to finalize this license agreement with Pneuma Respiratory." The commitment of a leading digital pulmonary drug management company is a valuable endorsement of our portfolio. that Pneuma's digital inhaler technology combined with our antibodies will create exciting new opportunities for both companies, and we look forward to working with Pneuma to bring our candidate drugs to medical centers as soon as possible. "
